CKD BURDEN
THE IMPACT OF CHRONIC KIDNEY DISEASE ON PATIENTS WITH TYPE 2 DIABETES IS FAR-REACHING1-8
As of 2021, approximately 537 million adults ages 20-79 have diabetes worldwide, of which around 90% have T2D. Up to 40% of patients with T2D develop chronic kidney disease.1,2
CKD can shorten life expectancy of patients with diabetes by up to 16 years, relative to the general population with neither disease.3*
Despite the standard treatments for ESRD (transplant or dialysis), once patients reach ESRD, approximately 60% will die in the next 5 years.4,5
Patients with stage 3 CKD are 10x more likely to die from any cause (including CV disease) than to progress to stage 5 CKD, dialysis, or kidney transplantation.6†
Patients with CKD associated with T2D have a 2x greater risk of developing heart failure than patients with T2D alone.7‡
Patients with T2D and CKD are at least 3x more likely to die of CV-related causes than patients with T2D alone.8§
Delays to diagnosis of CKD can have devastating consequences for patients with T2D, such as early death from CV causes or the need for dialysis or a kidney transplant9-11
COMPARED WITH T2D ALONE, COMORBID KIDNEY DISEASE INCREASES CV MORTALITY8
The increased risk of CV events associated with CKD and T2D appears early and grows with disease severity12
* | A prospective cohort study of 543,412 adult patients undergoing a private health surveillance programme in Taiwan.3 |
† | Analysis of 3,047 patients in Tromsø, Norway, with CKD using hospital records of serum creatinine, eGFR, treatment initiation, and death.6 |
‡ | T2D patients without baseline CV or renal disease (n=772,336), found through European and Japanese healthcare records, were followed for a mean of 4.5 years in order to assess the development of such disease.7 |
§ | Medical information from 15,046 patients in the NHANES programme in the US, analysed to assess the impact of CKD and T2D on death within 10 years.8 |
CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; ESRD=end-stage renal disease; NHANES=National Health and Nutrition Examination Survey; T2D=type 2 diabetes.
References:
- International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels; 2021. Accessed May 10, 2022. Available at: https://www.diabetesatlas.org. Return to content
- Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
- Wen CP, et al. Kidney Int. 2017;92(2):388-0396. Return to content
- Breyer M, et al. Nature. 2016;15. doi:10.1038/nrd.2016.67. Return to content
- Palsson, R, et al. Adv Chronic Kidney Dis. 2014;21(3):273-280. Return to content
- Eriksen BO, et al. Kidney Int. 2006;69(2):375-382. Return to content
- Birkeland K, et al. Diabetes Obes Metab. 2020;22:1607-1618. Return to content
- Afkarian M, et al. J Am Soc Nephrol. 2013;24(2):302-308. Return to content
- American Diabetes Association Professional Practice Committee. Diabetes Care. 2022;45(suppl 1):S1-S264. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1-150. Return to content
- Skolnik NS, et al. Diabetes Ther. 2021;12(6):1613-1630. Return to content
- Amod A, et al; DEVOTE Study Group.Diabetes Ther. 2020;11(1):53-70. Return to content
- Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25:181-191. Return to content
- Black LM, et al. J Histochem Cytochem. 2019;67(9):663-681. Return to content
- Tesch GH, et al. Front Pharmacol. 2017;8. doi:10:10.3389/fphar.2017.00313. Return to content
- Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010. Return to content
Follow:
© 2022 Bayer AG
Last updated in June 2022
This website is intended to provide information to an international audience of healthcare professionals outside the USA and UK.
- PP-KER-ALL-0077-1
